Mizuho Securities USA LLC Raises Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Mizuho Securities USA LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 45.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 16,342 shares of the medical research company's stock after purchasing an additional 5,112 shares during the period. Mizuho Securities USA LLC's holdings in IQVIA were worth $3,211,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Private Trust Co. NA grew its stake in shares of IQVIA by 10.7% in the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company's stock valued at $115,000 after buying an additional 47 shares in the last quarter. Pine Valley Investments Ltd Liability Co boosted its holdings in IQVIA by 0.5% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock valued at $2,247,000 after acquiring an additional 50 shares during the period. Howard Capital Management Inc. grew its position in IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock valued at $225,000 after acquiring an additional 54 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in IQVIA by 1.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock worth $1,068,000 after purchasing an additional 56 shares during the period. Finally, Cypress Wealth Services LLC lifted its position in shares of IQVIA by 4.8% during the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock worth $244,000 after purchasing an additional 57 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

IQV has been the topic of several recent research reports. BTIG Research downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Citigroup cut their price objective on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Barclays decreased their target price on IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a report on Monday, February 3rd. UBS Group cut their price target on IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Finally, Stifel Nicolaus decreased their price objective on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $249.05.

IQVIA Price Performance

IQV stock traded down $5.13 during trading on Tuesday, reaching $180.98. 806,492 shares of the company were exchanged, compared to its average volume of 1,239,209. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $254.54. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market cap of $31.91 billion, a P/E ratio of 24.16, a PEG ratio of 1.99 and a beta of 1.50. The stock's 50 day moving average price is $194.58 and its 200 day moving average price is $207.73.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.